Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01899365
Other study ID # 12-09
Secondary ID 2013-A00943-42
Status Completed
Phase
First received
Last updated
Start date November 2015
Est. completion date October 2017

Study information

Verified date October 2017
Source Centre Hospitalier Princesse Grace
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background :

Community-acquired pneumonia (CAP) is a threat in industrialized countries. It represents the 6th cause of death. CAP also frequently associates with other disorders responsible for admission and death. Among bacteria responsible for CAP, Streptococcus pneumonia is a major pathogen that is commonly involved and frequently leads to severe infection and admission. Categories at risk for this pathogen have been determined, and can be proposed anti-pneumococcal vaccination (APV) that efficiently and safely protects from this microorganism.

In the context of US health services, monocenter pilot experiences have reported improvement of pneumococcal prophylaxis implementing vaccination procedure at ED. A study that set in New Mexico (2003) reported a significant increase in APV (from 18% to 84%) when patients at risk were proposed vaccination at ED. To obtain these results, medical students were specifically trained and dedicated to screen and vaccinate against St. pneumoniae. Another single center trial (Tennessee, 2007) for APV at ED obtained an improvement (from 38.8 to 45.4%) when physicians were alerted for pneumococcal risk by the software they usually utilized at bedside. However these experiences remain sparse as additional dedicated resources are required or patients and attending ED physicians can be reluctant to proceed to vaccination at ED.

Mobile phone and derived communication modalities are current vectors to deliver information in several fields including education and medicine. Initially used in developing countries, short-message services (SMS) have improved behaviour of patients in various medical areas. In France, the investigators have observed that most patients above 50 years of age admitted after ED visit are equipped with mobile phone and can receive alerts by SMS.

These observations prompt us to propose a multifaceted procedure to improve APV after ED visit in at-risk patients, combining structured oral interview, written information and SMS as reminders.

Purpose : The investigators hypothesized that

- a multifaceted intervention to promote anti-pneumococcal vaccination combining a structured oral interview, a written information to patient and his/her general practitioner, and a series of 3 SMS,

- improves anti-pneumococcal vaccination at 6 months,

- in at-risk patients (65+ years) visiting the emergency department. In order to answer this question, the investigators designed an interventional prospective multicenter randomized study (cluster).


Recruitment information / eligibility

Status Completed
Enrollment 1475
Est. completion date October 2017
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- patients 65-year old and above,

- benefit from French or Monaco social security a social security.

Exclusion Criteria:

- refuse to participate,

- no possibility to receive SMS,

- impaired cognitive functions and mental status precluding understanding of the study,

- anticipated barriers precluding adequate follow-up (ex. homeless),

- previous APV,

- contraindication to APV,

- do not understand/read French.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Centre Hospitalier Universitaire de Clermont-Ferrand Clermont-ferrand
France Centre Hospitalier Paul Ardier Issoire
France AP-HM - Hôpital Nord Marseille
France AP-HM - La Timone Marseille
France HIA Laveran Marseille
France Centre Hospitalier La Palmosa Menton
France Centre Hospitalier Universitaire de Nice Nice
France Centre Hospitalier Louis Giorgi Orange
France Hôpital Bichat-Claude Bernard Paris
France Hôpital Cochin Paris
France Hôpital Lariboisière Paris
France Hôpital Pitié-Salpêtrière Paris
France Hôpital Tenon Paris
France Centre hospitalier de Saint-Denis Saint-denis
France Centre Hospitalier de Vaison-la-Romaine Vaison-la-romaine
France Centre Hospitalier Jules Niel Valreas
France Centre Hospitalier Jacques Lacarin Vichy
Monaco Centre Hospitalier Princesse Grace Monaco

Sponsors (3)

Lead Sponsor Collaborator
Centre Hospitalier Princesse Grace Centre Scientifique de Monaco, Pfizer

Countries where clinical trial is conducted

France,  Monaco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact of a multifaceted procedure at ED visit on anti-pneumococcal vaccination. (APV) at 6-month. Evaluation criteria : ? percentage (%) of APV vaccination at 6-month 6 month
Secondary On Flu vaccination at 6-month ? percentage (%) number of patients receiving vaccination against flu at 6-month. This issue will be collected by phone (patient, relative or general practioner). This will be a declarative data 6 month
Secondary On episodes of respiratory tract infections requiring antibiotics or admission at 6-month ? (absolute number of events) number of patients who experienced respiratiory tract infection requiring antibiotics or admission. This issue will be collected by phone at 6-month (patient, relative or general practioner). This will be a declarative data 6 month
Secondary On death at 6- and 12-month (absolute number of events) 6 month
Secondary On death related to infection at 6- and 12-month (absolute number of events) 6 month
Secondary Psychosocial evaluation of patients and acceptance / refusal of vaccination The patient will fil a Psychosocial evaluation questionnaire during the ED visit. To achieve this issue, we will use the socio-economic indicators mobilized in investigations in social epidemiology: sex, age, education, occupation, housing, income and household size. This composite questionnaire will be used for qualitative analysis. 6 month
See also
  Status Clinical Trial Phase
Completed NCT02201030 - Immunogenicity and Safety Study of NBP606 in Healthy Infants Phase 3
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Completed NCT04031846 - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Phase 3
Recruiting NCT05920499 - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage N/A
Completed NCT01215175 - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001) Phase 1
Completed NCT02892812 - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults Phase 1
Completed NCT02116998 - Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae Phase 2
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01193582 - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria Phase 4
Completed NCT00744263 - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults Phase 4
Completed NCT00492557 - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults Phase 3
Completed NCT00195611 - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media Phase 4
Completed NCT00137605 - Early Versus Delayed Pneumococcal Vaccination in HIV Phase 1/Phase 2
Completed NCT00205803 - Study Evaluating Pneumococcal Vaccine in Healthy Infants Phase 1/Phase 2
Completed NCT02531373 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005) Phase 1/Phase 2
Completed NCT03615482 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU) Phase 3
Completed NCT03565900 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) Phase 3
Completed NCT04989465 - A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Phase 4
Completed NCT02547649 - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006) Phase 2
Completed NCT02573181 - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) Phase 2